SEC Form 4 · accession 0001209191-16-153912
MAGELLAN HEALTH INC · MGLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan N Rubin
Officer — Chief Financial Officer
Period of report
Dec 6, 2016
Accepted (ET)
Dec 7, 2016 · 4:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000019411
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Common Stock, $0.01 par value | Dec 6, 2016 | X | 13,013 | $53.00 | A | 33,134 | D | |
| Ordinary Common Stock, $0.01 par value | Dec 7, 2016 | X | 29,953 | $53.00 | A | 63,087 | D | |
| Ordinary Common Stock, $0.01 par valueF2 | Dec 6, 2016 | S | 13,013 | $73.0484 | D | 50,074 | D | |
| Ordinary Common Stock, $0.01 par valueF3 | Dec 7, 2016 | S | 29,953 | $73.3649 | D | 20,121 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5,F4 | $53.00 | Dec 6, 2016 | X | 13,013 | D | — | Mar 5, 2023 | Common Stock | 13,013 | 29,953 | D |
| Stock Option (right to buy)F5,F4 | $53.00 | Dec 7, 2016 | X | 29,953 | D | — | Mar 5, 2023 | Common Stock | 29,953 | 0 | D |
Explanation of responses
- F1This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.
- F2The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from $73.00 to $73.30 inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- F3The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from $73.00 to $73.70 inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- F4All of the stock options in this tranche have vested in full.
- F5Not applicable.